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Abstract: Context: Fibromyalgia is a chronic musculoskeletal pain disorder. The pain can be intractable and may not 
respond to commonly-used treatments, such as tricyclic antidepressants and opioids. 
Objectives: To evaluate pregabalin response in the subset of patients with fibromyalgia whose pain had been judged 
refractory to other treatments. 
Methods: Patients had previously participated in a controlled trial of pregabalin and had moderate to severe pain despite 
treatment with gabapentin, a tricyclic antidepressant, and a third medication (e.g., other anticonvulsants, opioid, selective 
serotonin reuptake inhibitors, tramadol). Flexible-dose pregabalin 150-600 mg/day was added for 3-month treatment 
cycles, each followed by 3- to 28-day pregabalin “drug holiday” that lasted until a relapse occurred. Pain intensity was 
measured using the visual analogue scale of the Short-Form McGill Pain Questionnaire completed at baseline, the end of 
each 3-month treatment period and at the relapse visit. Analysis was at 15 months (after 5 cycles). 
Results: In total, 25 patients were included and 19 completed the 15-month analysis period. At baseline, 88% were 
receiving  1 pain medication. Pregabalin 150-600 mg/day was associated with statistically significant, clinically 
meaningful pain reduction during each treatment cycle. Pain quickly returned to baseline levels during the “drug holidays” 
in a median time of 2-4 days. Somnolence (n=5) and dizziness (n=4) were the most common adverse events. 
Conclusions: These results suggest that pregabalin may be beneficial in patients with fibromyalgia who have had an 
unsatisfactory response to treatment with other medications. 
Keywords: Pregabalin, anticonvulsant, fibromyalgia, pain, refractory, relapse, chronic widespread pain, open-label. 
INTRODUCTION 
  Fibromyalgia (FM) is a chronic pain disorder 
characterized by widespread pain and tenderness in all four 
quadrants of the body [1]. The condition affects significantly 
more women than men, with worldwide prevalence estimates 
ranging from 0.5% to 5.0% [2]. The chronic widespread pain 
associated with fibromyalgia is often accompanied by other 
painful symptoms including joint pain, headache and low 
back pain [3], and additional disabling symptoms such as 
sleep disturbance and fatigue [1]. Fibromyalgia can be 
profoundly disabling and many studies have shown that 
people with FM have poor quality of life and substantial 
functional impairment [4, 5]. The economic burden of FM is 
substantial [6]. The etiology and pathogenesis of FM are not 
well understood, but it has been postulated that the condition 
is a rheumatologic disorder in which the associated pain is 
driven primarily by central sensitization that may involve 
several neuronal systems [7]. 
  Pharmacological treatment options for which there is 
supportive evidence include antidepressants, anticonvulsants 
and tramadol [8]. Three agents, pregabalin, duloxetine, and  
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milnacipran, are now approved by the Food and Drug 
Administration (FDA) in the United States for the 
management of FM [9]. Pregabalin is an 2- ligand with 
analgesic activity that is mediated by its ability to bind with 
high affinity to the 2- subunit of voltage-gated calcium 
channels in central nervous system (CNS) tissues [10]. 
Pregabalin 300-600 mg/day has been shown in controlled 
trials to be effective in the treatment of fibromyalgia [11-14] 
and in the treatment of neuropathic pain [15]. In this paper, 
we report the results from an analysis of patients with FM 
who were refractory to other treatments who had entered a 
long-term, open-label study of pregabalin after participating 
in a randomized controlled trial. 
MATERIALS AND METHODOLOGY 
Patients 
  Patients with FM according to American College of 
Rheumatology criteria [1] had taken part in an optional 
open-label extension trial that followed an 8-week multi-site 
controlled trial of pregabalin 150-600 mg/day [4]. After the 
extension study was closed, patients reverted to usual care. 
Patients must have received treatment with standard 
treatments (as defined below) for a total of at least 6 months 
before they were eligible to be enrolled into this study. All 
participants provided written, informed consent. The study 
was approved by Institutional Review Boards. 36   The Open Rheumatology Journal, 2010, Volume 4  Stacey et al. 
  To be eligible patients had to be refractory to treatment 
with gabapentin 1800 mg/day, a tricyclic antidepressant 
(TCA)  75 mg/day, and a third line medication, which 
included other anticonvulsants, opioid analgesics, compound 
analgesics, selective serotonin reuptake inhibitors (SSRIs), 
serotonin norepinephrine reuptake inhibitors (SNRIs), non-
steroidal anti-inflammatory drugs (NSAIDs), cyclooxy-
genase II inhibitors (Cox IIs) and tramadol. Refractoriness 
was defined as inadequate pain relief despite treatment for at 
least 2 weeks at or above the minimum dose and/or 
intolerable side-effects with each of the three medications or 
medication groups listed above. Patients were required to 
have a score of at least 40 mm on the 0-100 mm visual 
analogue scale (VAS) of pain intensity of the Short-Form 
McGill Pain Questionnaire (SF-MPQ; “no pain” to “worst 
possible pain”) [16]. Patients were allowed to remain on 
analgesic medications, including drugs to which they were 
refractory, and these could be adjusted during the study. 
  The details of the overall study and results for the 
patients with postherpetic neuralgia and diabetic peripheral 
neuropathy who entered this follow-on study have been 
reported elsewhere [17]. 
Study Design 
  Patients received flexible-dose pregabalin 150-600 
mg/day, taken three times a day (TID), for 3 months, 
followed by a 3 to 28-day period during which pregabalin 
was discontinued (“drug holiday”). The starting dosage of 
150 mg/day could be increased after 1 week, after which 
pregabalin dosing was flexible at the discretion of the 
investigator. Patients who experienced a relapse during each 
drug holiday were allowed to resume a further 3 months of 
treatment. Relapse was defined as scoring “moderately 
worse”, “much worse” or “very much worse” in answer to 
the question “how much has your pain worsened since 
discontinuing study medication?” Patients who did not 
relapse were discontinued. After four consecutive drug 
holidays, patients could continue pregabalin without further 
drug withdrawals. 
Assessments 
  At the end of each 3-month pregabalin treatment period 
patients were required have a clinical visit during which the 
SF-MPQ VAS was completed and adverse events were 
recorded. Patients who relapsed during the drug holiday 
were required to complete a pain VAS and have the relapse 
confirmed by the investigator. If a patient did not meet 
relapse criteria they could be assessed once more within the 
28-day drug holiday. Mean pain VAS scores were calculated 
at baseline, the end of each 3-month treatment period, and 
during the drug holidays. The distribution of patients with 
no/mild, moderate, and severe pain (no/mild pain = <40 mm; 
moderate pain = 40 to <70 mm; severe pain = 70 mm) at 
the 15 month endpoint was determined based on the last pain 
VAS score on pregabalin treatment carried forward. The 
numbers of patients with 30% and 50% reductions in the 
pain score from baseline to the end of the first 3-month 
treatment period and to the fifth 3-month treatment period 
endpoint were also determined in the same manner. The 
protocol for this study did not specify inferential testing of 
treatment effectiveness, but because of the unique nature of 
the study design and data, we performed analyses of the 
statistical significance of the mean changes from baseline in 
pain intensity as measured by the SF-MPQ VAS. The data 
examined in this report were limited to the first 15 months of 
pregabalin treatment of this trial because after that point the 
drug holidays were discontinued and the study became a 
standard open-label trial. 
RESULTS 
  In total, 25 patients with FM (76% female; mean age 54 
years) were enrolled into the study and are included in this 
analysis. The baseline characteristics for these patients are 
shown in Table 1. Most patients (88%) were taking other 
pain medications, despite being refractory to them, and 
almost 70% had severe pain at baseline. Of the 25 FM 
patients enrolled, 19 (76%) completed 15 months of 
pregabalin treatment. Reasons for discontinuation were as 
follows: two patients due to adverse events, one due to lack 
of efficacy, and three were non-compliant or discontinued 
for other reasons. Four out of the six patients who 
discontinued did so during the first 3-month treatment 
period. All patients relapsed during the four drug holidays. 
The median duration of each of the drug holidays was 3-4 
days (Table 1). The mean (standard deviation, SD) daily 
pregabalin dose was 385 (148) mg during the first 3 months, 
424 (168) mg from months 3-6 and 463 (151) mg from 
months 12-15. 
Table 1.  Patient Baseline Characteristics, Concomitant Pain 
Medication Use and Duration of Pregabalin Drug 
Holidays 
 
  FM (N=25) 
Baseline Characteristics 
Women n, (%)  19 (76.0) 
Age, mean (SD) years  54.2 (6.7) 
FM duration, mean (SD) years  11.0 (8.1) 
SF-MPQ pain VAS score, mean (SD) mm  73.6 (15.0) 
Patients in severe pain*, n (%)   17 (68) 
Pain Medications at Enrolment, n (%)† 
Any   22 (88.0) 
- Gabapentin  7 (28.0) 
- TCA  9 (36.0) 
- Other (3
rd line)  18 (72.0) 
Mean/Median Drug Holiday Duration, Days 
Drug holiday 1  7.4/4.0 
Drug holiday 2  3.8/3.0 
Drug holiday 3  5.7/3.0 
Drug holiday 4  5.6/3.0 
*Severe pain includes patients with SF-MPQ pain VAS 70mm. 
†Includes medications to which patients were refractory. 
 
  One patient did not have a post-baseline pain assessment 
so was not included in the analysis of pain. The mean SF-
MPQ VAS scores for each 3-month treatment period were 
similar, and were statistically significantly and substantially 
lower than the baseline score (Fig. 1). Mean pain scores on Pregabalin for Refractory Pain in FM  The Open Rheumatology Journal, 2010, Volume 4   37 
pregabalin treatment improved by 30% from baseline at 
endpoint. The reduction in pain scores observed in each 
treatment period ranged from 30 to 45%. During each of the 
drug holidays, mean pain VAS scores increased 
substantially, returning to at least baseline levels (Fig. 1). 
There was a notable change in the pain severity distribution 
between baseline and the 15-month endpoint (Fig. 2). At 3 
months of pregabalin treatment, 54% and 50% of patients 
had a 30 and 50% reduction in pain from baseline, 
respectively. At endpoint of pregabalin treatment, 46% and 
38% of patients had a 30 and 50% reduction in pain from 
baseline, respectively. Somnolence (5/25; 20%) and 
dizziness (4/25; 16%) were the most frequently reported 
treatment-emergent adverse events. 
 
*No/mild pain = <40 mm; moderate pain = 40 to <70 mm; severe pain = 70 
mm. 15-month endpoint is based on last observation carried forward. 
1 patient with moderate pain at baseline not included in the analysis because 
there was no post-baseline pain assessment. 
Fig. (2). Pain severity* distribution at baseline and the 15-month 
endpoint. 
DISCUSSION 
  This investigation of patients with longstanding, chronic 
FM who were refractory to the conventional treatments 
being used at the time of the study demonstrated a clinically 
meaningful pain reduction [18]
  with pregabalin treatment 
that was maintained for over a year.
 As was evident from the 
baseline pain scores patients continued to experience notable 
levels of pain despite being on treatment with TCAs, 
gabapentin and 3
rd line agents. Many such patients 
experience ongoing – often severe – pain and continue to 
take medications despite their limited effectiveness. 
  Pregabalin was associated with improvement in pain at 
the end of the first 3-month treatment period. Pain rapidly 
returned to pre-treatment levels soon after pregabalin was 
stopped for four mandatory drug holidays. This pattern of 
significant and substantial relief on pregabalin, followed by 
pain returning to baseline levels upon pregabalin 
discontinuation, was remarkably consistent throughout the 
five 3-month pregabalin treatment periods and four 
pregabalin drug holidays. Evidence of the clinical relevance 
of the improvement in pain with pregabalin treatment is 
provided by the fact that 68% of patients had severe pain at 
baseline and only 38% did so after 15 months of pregabalin 
treatment. Importantly, 42% of patients had no/mild pain at 
15 months. Around half the patients had a 30% reduction in 
pain after 3 and 15 months of treatment, further 
demonstrating that clinically meaningful pain relief was 
achieved and sustained with long-term pregabalin treatment. 
The mean changes in pain scores (~30%-45% across 
treatment periods) can also be considered clinical relevant 
[18], but concluding that the marked improvements in pain 
were entirely due to pregabalin is not possible because there 
was no control for placebo responses and other non-specific 
effects. 
  While the mean daily dose of pregabalin increased over 
the 15 months of this study, the effect of pregabalin was 
maintained at a mean dose (463 mg/day) just slightly above 
the subsequently FDA-approved therapeutic dosage range of 
150-450 mg/day. Pregabalin was generally well tolerated. 
The discontinuation rate due to adverse events was low (8%) 
and the most common adverse events, somnolence and 
dizziness, were consistent with previously reported 
controlled trials in fibromyalgia [11-14]. 
  Although the etiology and pathology of fibromyalgia 
remains to be established, recent evidence suggests that 
dysfunction within the CNS, including central sensitization, 
may be responsible for the chronic, widespread pain that is 
the hallmark of fibromyalgia [19, 20]. The precise 
mechanism of action of pregabalin that underpins the 
 
Fig. (1). Mean pain VAS scores during 3-month pregabalin treatment periods and during pregabalin drug holidays. 38   The Open Rheumatology Journal, 2010, Volume 4  Stacey et al. 
improvement in pain has not been fully elucidated. However, 
by binding to the 2- subunit of voltage-gated calcium 
channels in the CNS and modulating calcium channel 
function pregabalin has been shown to reduce 
neurotransmitter release from pre-synaptic, hyperexcited 
nerve terminals [10]. It has been proposed that via such 
actions pregabalin may modulate central sensitization, with a 
resultant analgesic effect [21]. 
CONCLUSION 
  This unique study enrolled treatment resistant patients 
that went through a mandatory drug withdrawal and 
subsequent relapse. This study demonstrated sustained 
pregabalin effect. The study has limitations due to its open-
label design involving a relatively small number of patients 
who had previously participated in a controlled clinical trial 
(and hence may be subject to selection bias). The results 
complement the findings of previously completed placebo-
controlled, double-blind studies in FM and suggest that 
pregabalin may provide clinically meaningful and sustained 
pain relief for patients with FM who are refractory to other 
commonly-used treatments. The most recent evidence-based 
guidelines specifically related to the management of FM 
have been developed by EULAR, and pregabalin is now a 
recommended treatment option [22]. Although evidence 
from the randomized, controlled clinical trials suggest that 
pregabalin is an effective first- or second-line option in FM it 
is reassuring that, based on the results of this study, the 
treatment also appears to offer a treatment option to patients 
who have failed to respond to previous treatment with 
commonly used agents, and also the potential to avoid 
stepping up to an opioid regimen. 
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